Quest Diagnostics Inc (DGX) FinancialsDGXFinancialQuest Diagnostics Inc

Quest Diagnostics Inc (DGX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Diagnostic Information Services Business, accounting for 97.8% of total sales, equivalent to $2.83B. Another important revenue stream is All other operating segments. Understanding this composition is critical for investors evaluating how DGX navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Quest Diagnostics Inc maintains a gross margin of 32.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.18%, while the net margin is 10.98%. These profitability ratios, combined with a Return on Equity (ROE) of 14.35%, provide a clear picture of how effectively DGX converts its operational activities into shareholder value.

In the context of the broader market, DGX competes directly with industry leaders such as ASTH and NRC. With a market capitalization of $25.87B, it holds a leading position in the sector. When comparing efficiency, DGX's gross margin of 32.53% stands against ASTH's 9.10% and NRC's 56.41%. Such benchmarking helps identify whether Quest Diagnostics Inc is trading at a premium or discount relative to its financial performance.

Quest Diagnostics has shown impressive financial performance with a year-to-date change of +39.69% and a 1-year change of +35.85%. The latest earnings report showed an adjusted EPS of $3.12, which was an 11.03% surprise over estimates, indicating strong operational efficiency.